Glochem

What Glochem does

Glochem Industries Private Limited is a privately held Indian pharmaceutical manufacturer founded in 1995/1996 and headquartered in Hyderabad, Telangana, that develops, produces, and markets Active Pharmaceutical Ingredients (APIs) for global formulation companies. Its commercial portfolio consists of eight regulated APIs spanning cardiovascular (Amlodipine Besylate and its S-isomer and Maleate variants, Telmisartan, Clopidogrel Bisulphate Form II), antihistamine (Cetirizine Dihydrochloride, Levocetirizine Dihydrochloride, Hydroxyzine HCL), and SERM (Raloxifene HCl) categories, plus two captive intermediates (Phthalimido Amlodipine and Amlodipine Base). Three additional molecules (Famotidine, Lercanidipine, Empagliflozin) are in development with US DMF filings targeted through 2025. Manufacturing is concentrated at the USFDA-, EU-GMP-, PMDA-, KFDA-, TGA-, WHO-GMP- and ANVISA-approved Bollaram facility in Hyderabad, with 82.8 KL of installed reactor capacity across 39 reactors, ISO Class 8 clean rooms, and a 100 KLD MEE/ZLD system added in 2022.

The business model is B2B direct-to-formulator with no intermediaries: revenue is generated from one-time purchases of API batches plus CMO contracts (e.g., the 2019 Melody agreement for Raloxifene), with pricing set on a quote basis tied to volume, regulatory documentation (DMF/CEP), and jurisdictional compliance requirements. Go-to-market relies on direct sales engagement, regulatory filings, and trade-show presence (CPHI), with distribution spanning 50+ countries including the USA, all EU member states, the UK, Japan, Korea, Bangladesh, the Middle East, South America, and CIS countries. Glochem also markets impurity reference standards and pharmacopoeial working standards (EP, USP, IP, JP) for its API portfolio, which support internal quality control and external sales to analytical labs.

Glochem has no disclosed external equity investors and is owned/operated by a professional management team led by MD & CEO Chandra Kumar Verma and CSO Dr. Mayur Khunt, with senior officers drawn from Pfizer, Dr. Reddy's, Mylan, Aurobindo, Alembic, and Actavis/TEVA. The corporate history reflects a focused strategy: divestitures of the Jadcherla FDF (to Mylan, 2013) and Vizag facility (to Torrent, 2016) were offset by the 2019 re-acquisition of Raloxifene with its DMF/CEP, conversion to a Private Limited company in 2017, and ongoing physical expansion at Bollaram plus a planned 10-acre greenfield in Kadechur. As of FY2023, the company reports approximately 165 employees and $18 million USD in annual revenue, consistent with a mid-sized regulated API producer rather than a scaled platform.

Name

Glochem

Legal name

Glochem Industries Private Limited

Website

https://glochemindia.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

Glochem Industries Private Limited is a Hyderabad-based, privately held pharmaceutical manufacturer that develops and supplies regulated Active Pharmaceutical Ingredients (APIs) — including Amlodipine, Cetirizine, Levocetirizine, Raloxifene, Telmisartan, Clopidogrel, and Hydroxyzine — directly to global formulation manufacturers across 50+ countries.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Active pharmaceutical ingredients
• API manufacturing
• Pharmaceutical intermediates
• Impurity reference standards
• Contract manufacturing

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Manufacturing and Sales: Developing, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) with comprehensive documentation to highly regulated global markets. Core revenue stream from established APIs including Amlodipine Besylate, Cetirizine, Levocetirizine, Telmisartan, Raloxifene, Hydroxyzine HCL, Clopidogrel Bisulphate.
2. Intermediate Products: Manufacturing and supply of pharmaceutical intermediates including Phthalimido Amlodipine and Amlodipine Base for use in downstream API synthesis.
3. Contract Manufacturing (CMO Services): CMO agreement with Melody for Raloxifene API manufacturing. Adding CMO sites to DMFs to expand market reach and production capacity.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Core offering

Glochem Industries Private Limited develops, manufactures, and markets Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and impurity/working reference standards for sale to global pharmaceutical formulation manufacturers. Core APIs include Amlodipine Besylate, S(-)Amlodipine Besilate, Amlodipine Maleate, Cetirizine and Levocetirizine Dihydrochloride, Raloxifene HCl, Hydroxyzine HCL, Telmisartan, and Clopidogrel Bisulphate Form II. The company also offers CMO (Contract Manufacturing Organization) services for partner companies under CMO agreements, with CMO sites added to existing DMFs to expand market reach and production capacity.

Product overview

Glochem Industries Private Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates for regulated global markets. The company's core portfolio includes nine commercial APIs: Amlodipine Besylate (with S-isomer and Maleate variants), Cetirizine and Levocetirizine Dihydrochloride, Raloxifene HCl, Hydroxyzine HCL, Telmisartan, and Clopidogrel Bisulphate. The company also manufactures intermediate products for Amlodipine synthesis. Glochem offers pharmaceutical impurity reference standards and working standards for quality control purposes. Three products are under development: Famotidine, Lercanidipine, and Empagliflozin targeting DMF filings through 2025. Manufacturing is conducted at USFDA, EU-GMP, TGA, PMDA, and KFDA-approved facilities in Bollaram, Hyderabad.

Differentiator

Problem solved

Functional benefit

Products and services

• Amlodipine Besylate API Calcium channel blocker API used in formulations for the treatment of hypertension and angina. One of Glochem's flagship APIs, manufactured at the Bollaram facility and supplied to global pharmaceutical formulation manufacturers.
• S(-)Amlodipine Besilate API Enantiomerically pure (S)-isomer of Amlodipine Besylate with enhanced stereochemical purity, targeted at formulations requiring single-enantiomer drug substance. Currently under regulatory review in the EU.
• Amlodipine Maleate API Alternative salt form of Amlodipine for formulations targeting hypertension treatment. Currently under regulatory review in the EU.
• Cetirizine Dihydrochloride API Second-generation antihistamine API used in formulations for allergic rhinitis and chronic urticaria. A key Glochem product with multiple regulatory approvals.
• Levocetirizine Dihydrochloride API Third-generation antihistamine API, the active enantiomer of Cetirizine, used in formulations for allergic conditions. Has received the Certificate of Suitability (CEP) from EDQM and is under regulatory review in the EU and Russia.
• Raloxifene HCl API Selective estrogen receptor modulator (SERM) API used in formulations for osteoporosis treatment and breast cancer prevention. DMF and CEP originally filed in 2007.
• Hydroxyzine HCL API First-generation antihistamine API with anxiolytic properties used in formulations for anxiety and allergic conditions. DMF filed in the US; under regulatory review in Russia.
• Telmisartan API Angiotensin II receptor antagonist API used in formulations for hypertension treatment. DMF filed in the US; under regulatory review in the EU.
• Clopidogrel Bisulphate Form II API Antiplatelet agent API used in formulations for the prevention of atherosclerotic events. Manufactured at Glochem's Bollaram facility.
• Phthalimido Amlodipine Intermediate Key intermediate used in the synthesis of Amlodipine Besylate (CAS #88150-62-3). Sold to other pharmaceutical companies as a building block for downstream API manufacturing.
• Amlodipine Base Intermediate Core Amlodipine intermediate in free base form (CAS #88150-47-4). Used in downstream API synthesis by other pharmaceutical manufacturers.
• Impurity Reference Standards Pharmaceutical impurity reference standards covering Amlodipine, Cetirizine, Telmisartan, Raloxifene, Clopidogrel, and Hydroxyzine impurities. Developed with EP, USP, and in-house monographs and supplied for analytical and quality control use.
• Working Standards EP, USP, IP, and JP working standards for Amlodipine Besylate, Cetirizine Di Hydrochloride, Telmisartan, Raloxifene, and Levocetirizine, used as quality reference materials in pharmaceutical analysis.
• Contract Manufacturing (CMO) Services Contract manufacturing services for API production under CMO agreements, with CMO sites added to partner-owned DMFs to expand production capacity and market reach.

Quantifiable outcome

• USFDA, EUGMP, TGA, PMDA, KFDA, WHO GMP, ANVISA approvals for manufacturing facility
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• The Handloom Future TrustminorOthers · 26 March 2025CSR partnership for Artisan Empowerment Initiative preserving India's handloom heritage. Contribution of ₹5,00,000 on 26 March 2025.
• Akshaya Vidya (Inclusive Education)minorOthers · 26 March 2025CSR partnership for Inclusive Education for Slum Communities supporting learning centres. Contribution of ₹2,00,000 on 26 March 2025.
• Smart Andhra Pradesh FoundationminorOthers · 13 September 2024CSR partnership for Disaster Management Support under Chief Minister's Relief Fund framework. Contribution of ₹3,00,000 on 13 September 2024.
• Akshaya Patra FoundationminorOthers · 17 August 2024CSR partnership for Mid-Day Meal Programme supporting school meals in government schools. Contribution of ₹3,00,000 on 17 August 2024.
• Akshaya VidyaminorOthers · 4 May 2024CSR partnership for Slum Education Project supporting evening learning centres for underserved children in Hyderabad. Contribution of ₹1,00,000 on 04 May 2024.
• MelodycoreStrategic or Co-development Partner · 1 January 2019CMO (Contract Manufacturing Organization) agreement signed in 2019 for Raloxifene API manufacturing. Glochem provides manufacturing services to Melody under this agreement.
• OrganosyncoreStrategic or Co-development Partner · 1 January 2013Joint venture partnership in 2013 to establish Evertogen as a new FDF (Finished Dosage Form) company. Combined Glochem's API capabilities with Organosyn's formulation expertise.
• AcinocoreStrategic or Co-development Partner · 1 May 2004Strategic partnership established in 2004-05 for filing DMFs and CEPs starting with EU and Canada markets. Acino was a key early partner for Glochem's international regulatory filing strategy.

Scale indicators12 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• MSN Laboratories: Hyderabad-based Indian API manufacturer with similar focus on small-molecule APIs for regulated global markets (USFDA, EU-GMP). Comparable scale and business model of supplying high-quality APIs to formulation companies.
• Hetero Labs: Indian API and finished dosage manufacturer with deep focus on regulated markets. Competes directly with Glochem in generic small-molecule APIs including cardiovascular and central nervous system therapeutic categories.
• Alembic Pharmaceuticals: Indian API manufacturer and former employer of Glochem's CSO Dr. Mayur Khunt. Operates in similar generic API categories with USFDA/EU-GMP-certified facilities, making it a directly comparable peer in capabilities and customer base.
• Hikal Limited: Indian API manufacturer and CDMO with focus on regulated markets. Also a former employer of Glochem's CSO. Comparable in API manufacturing capabilities, regulatory footprint, and customer base in pharma formulation.
• Solara Active Pharma Sciences: Indian API manufacturer with USFDA, EU-GMP, and other regulatory approvals focused on supplying APIs globally. Directly comparable in scale, regulatory focus, and small-molecule API manufacturing business model.
• Cohance Lifesciences (formerly part of Advent International portfolio): Indian API platform previously associated with Glochem CSO's background. Operates API manufacturing for regulated markets with CDMO capabilities—directly comparable business model and customer segments.
• Symer Lifesciences (formerly Symed Labs): Indian API CDMO focused on complex small-molecule APIs for regulated markets. Comparable in scale, regulatory positioning, and contract manufacturing services similar to Glochem's CMO offering.

Broad incumbents

• Aurobindo Pharma: One of India's largest API and finished dosage manufacturers. Competes in many of the same generic API categories as Glochem (cardiovascular, antihistamines) but at substantially larger scale and broader product portfolio.
• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with substantial API manufacturing operations and global regulatory footprint. Former employer of multiple Glochem senior leaders; overlaps in API categories and regulated market customers.
• Granules India: Indian API and finished dosage manufacturer with USFDA-approved facilities. Operates at larger scale than Glochem in similar small-molecule API categories, supplying global formulation companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/827569/admin/page-posts/published
• Facebookfacebook.com/328016834279403

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glochem